Development of the Commercial Manufacturing Process for Ipatasertib

Area of Science:

• Medicinal Chemistry
• Process Chemistry
• Drug Development

Background:

• Ipatasertib is a potent Akt kinase inhibitor.
• It is undergoing Phase III clinical trials for metastatic castration-resistant prostate cancer and triple-negative metastatic breast cancer.

Purpose of the Study:

• To provide an overview of the development achievements for the commercial manufacturing process of Ipatasertib.
• To describe the synthetic strategies employed for this complex molecule.

Main Methods:

• A convergent synthesis approach was developed.
• The synthesis involves ten steps with eight isolated intermediates.
• Enzyme and metal catalysis were utilized to introduce stereocenters.

Main Results:

• A viable ten-step convergent synthesis for Ipatasertib was established.
• The process incorporates diverse chemical techniques and technologies.
• Stereochemical control was achieved through catalytic methods.

Conclusions:

• The developed manufacturing process is suitable for commercial production.
• The synthesis highlights advancements in complex drug manufacturing.
• Ipatasertib's production pathway is optimized for efficiency and stereochemical integrity.